A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
Public ClinicalTrials.gov record NCT01636843. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomised, Double Blind, Placebo-controlled, Multiple Dose, Phase 2b, 24 Week Trial Followed by an Open Label Extension of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This trial is conducted in Europe, North America and South America. The aim of this trial is to investigate the clinical efficacy of NNC0109-0012, a human monoclonal antibody, compared to placebo when administered as weekly repeat subcutaneous (under the skin) injections in to patients with active rheumatoid arthritis (RA) with inadequate responses to methotrexate (MTX) while on a stable background of MTX therapy.
Study identification
- NCT ID
- NCT01636843
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 298 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 29, 2012
- Primary completion
- Nov 9, 2014
- Completion
- Nov 9, 2014
- Last update posted
- Sep 4, 2018
2012 – 2014
United States locations
- U.S. sites
- 29
- U.S. states
- 20
- U.S. cities
- 29
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novo Nordisk Investigational Site | Huntington Beach | California | 92646 | — |
| Novo Nordisk Investigational Site | La Mesa | California | 91942 | — |
| Novo Nordisk Investigational Site | Los Angeles | California | 90022 | — |
| Novo Nordisk Investigational Site | Placentia | California | 92870 | — |
| Novo Nordisk Investigational Site | Upland | California | 91786 | — |
| Novo Nordisk Investigational Site | Palm Harbor | Florida | 34684 | — |
| Novo Nordisk Investigational Site | Rock Island | Illinois | 61201 | — |
| Novo Nordisk Investigational Site | Springfield | Illinois | 62704 | — |
| Novo Nordisk Investigational Site | South Bend | Indiana | 46601 | — |
| Novo Nordisk Investigational Site | Cedar Rapids | Iowa | 52401-2112 | — |
| Novo Nordisk Investigational Site | Wichita | Kansas | 67206 | — |
| Novo Nordisk Investigational Site | Elizabethtown | Kentucky | 42701-2988 | — |
| Novo Nordisk Investigational Site | Lake Charles | Louisiana | 70601 | — |
| Novo Nordisk Investigational Site | Hagerstown | Maryland | 21740 | — |
| Novo Nordisk Investigational Site | St Louis | Missouri | 63117 | — |
| Novo Nordisk Investigational Site | Kalispell | Montana | 59901 | — |
| Novo Nordisk Investigational Site | Freehold | New Jersey | 07728 | — |
| Novo Nordisk Investigational Site | Toms River | New Jersey | 08755 | — |
| Novo Nordisk Investigational Site | Albuquerque | New Mexico | 87102 | — |
| Novo Nordisk Investigational Site | Brooklyn | New York | 11201-4326 | — |
| Novo Nordisk Investigational Site | Lake Success | New York | 11042 | — |
| Novo Nordisk Investigational Site | Charlotte | North Carolina | 28210 | — |
| Novo Nordisk Investigational Site | Norman | Oklahoma | 73069 | — |
| Novo Nordisk Investigational Site | Orangeburg | South Carolina | 29118 | — |
| Novo Nordisk Investigational Site | Jackson | Tennessee | 38305 | — |
| Novo Nordisk Investigational Site | Memphis | Tennessee | 38119 | — |
| Novo Nordisk Investigational Site | Houston | Texas | 77008 | — |
| Novo Nordisk Investigational Site | Mesquite | Texas | 75150-5615 | — |
| Novo Nordisk Investigational Site | Beckley | West Virginia | 25801-2805 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 110 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01636843, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 4, 2018 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01636843 live on ClinicalTrials.gov.